The estimated Net Worth of Barry D Quart is at least $6.02 Milión dollars as of 5 June 2024. Barry Quart owns over 4,373 units of Heron Therapeutics Inc stock worth over $16,965 and over the last 10 years he sold HRTX stock worth over $130,700. In addition, he makes $5,870,480 as Chairman of the Board a Chief Executive Officer at Heron Therapeutics Inc.
Sign up
Barry Quart HRTX stock SEC Form 4 insiders trading
Barry has made over 26 trades of the Heron Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 4,373 units of HRTX stock worth $7,915 on 5 June 2024.
The largest trade he's ever made was exercising 100,000 units of Heron Therapeutics Inc stock on 19 March 2018 worth over $720,000. On average, Barry trades about 12,492 units every 93 days since 2014. As of 5 June 2024 he still owns at least 9,373 units of Heron Therapeutics Inc stock.
You can see the complete history of Barry Quart stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Barry Quart biography
Dr. Barry D. Quart Pharm.D. serves as Chairman of the Board, Chief Executive Officer of the Company. Dr. Quart was appointed Chief Executive Officer in 2013 and President and Chief Executive Officer in February 2019. He has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through 2013, and as a director through its acquisition by AstraZeneca PLC in 2012. Previously, he was with Pfizer Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. He joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in 2015. Since 2015, he has served as a director of Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.
What is the salary of Barry Quart?
As the Chairman of the Board a Chief Executive Officer of Heron Therapeutics Inc, the total compensation of Barry Quart at Heron Therapeutics Inc is $5,870,480. There are no executives at Heron Therapeutics Inc getting paid more.
How old is Barry Quart?
Barry Quart is 63, he's been the Chairman of the Board a Chief Executive Officer of Heron Therapeutics Inc since 2020. There are 1 older and 20 younger executives at Heron Therapeutics Inc. The oldest executive at Heron Therapeutics Inc is Dr. Barry D. Quart, 64, who is the Chairman & CEO.
What's Barry Quart's mailing address?
Barry's mailing address filed with the SEC is C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE 2 CHURCH STREET, HAMILTON, D0, HM 11.
Insiders trading at Heron Therapeutics Inc
Over the last 11 years, insiders at Heron Therapeutics Inc have traded over $96,663,574 worth of Heron Therapeutics Inc stock and bought 6,549,746 units worth $56,275,132 . The most active insiders traders include Kevin Ctang Capital Managem..., Adam Morgan a Craig A Collard. On average, Heron Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $176,989. The most recent stock trade was executed by Craig A Collard on 19 July 2024, trading 13,797 units of HRTX stock currently worth $24,973.
What does Heron Therapeutics Inc do?
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
What does Heron Therapeutics Inc's logo look like?
Complete history of Barry Quart stock trades at Heron Therapeutics Inc a Kiniksa Pharmaceuticals International Plc
Heron Therapeutics Inc executives and stock owners
Heron Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Barry Quart,
Chairman of the Board, Chief Executive Officer -
John Poyhonen,
President and Chief Commercial Officer -
Kimberly Manhard,
Executive Vice President - Drug Development, Director -
Dr. Barry D. Quart,
Chairman & CEO -
Kimberly J. Manhard,
Exec. VP of Drug Devel. & Director -
John W. Poyhonen,
Pres & Chief Commercial Officer -
David L. Szekeres,
Exec. VP & COO -
Stephen Davis,
Independent Director -
Craig Johnson,
Lead Independent Director -
Christian Waage,
Independent Director -
Lisa Peraza,
Chief Accounting Officer, Vice President -
John Arthur,
Vice President - Manufacturing and Supply -
Sean Ristine,
Vice President - Human Resources -
Christopher Storgard,
Chief Medical Officer -
Thomas Ottoboni,
Senior Vice President - Pharmaceutical and Translational Sciences, Chief Scientific Officer -
Michael Mathews,
Senior Vice President - Pain Franchise -
Anita Gupta,
Senior Vice President - Medical Strategy and Government Affairs -
David Szekeres,
Chief Operating Officer, Executive Vice President -
Dr. Chris M. Storgard,
Chief Medical Officer -
Michael E. Mathews,
Sr. VP of Acute Care -
Dr. Thomas B. Ottoboni,
Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences -
Sean T. Ristine,
Sr. VP of HR -
Sharmila Dissanaike,
Director -
Paul Marshall,
SVP, Technical Operations -
Robert Rosen,
President -
Kevin Ctang Capital Managem...,
-
Brian G. Drazba,
VP, Finance & CFO -
Robert Hoffman,
CFO & SVP, Finance -
Kevin C Tang,
Director -
Mark S. Md Gelder,
SVP & Chief Medical Officer -
Neil James Clendeninn,
SVP & Chief Medical Officer -
Susan Rodriguez,
Director -
Adam Morgan,
Director -
Craig A Collard,
Chief Executive Officer -
William P Forbes,
EVP, Chief Development Officer -
Ira Duarte,
EVP, Chief Financial Officer